


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

1. (Currently amended) A method for ~~preventing or treating dementia~~ improving memory performance in an animal, the method comprising:  
~~providing~~ administering a therapeutically effective dose of a derivative of a succinate ester of general formula (I), or a stereo-isomer or a pharmaceutically acceptable salt thereof:




wherein,

R<sub>1</sub> and R<sub>4</sub> are selected from -OCH<sub>3</sub>, -OH, -O-Glu,



R<sub>2</sub> and R<sub>3</sub> are selected from H, -OH, -O-Glu,




R<sub>5</sub> is selected from non-branched or branched C<sub>1-6</sub> alkyls; and

the configuration of chiral center at C-2 and C-3 are 2R3S, 2R3R, 2S3S and 2S3R respectively.


~~; and administering the succinate ester derivative to a patient.~~

2. (Currently amended) The method according to claim 1, characterized in that said compound of formula (I) is:




or a stereo-isomer or a pharmaceutically acceptable salt thereof, wherein R<sub>5</sub> is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl; and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are the same as that in claim 1.






3. (Currently amended) The method according to claim 2 characterized in that said compounds include:




;








;





1,4-bis(β-D-glucopyranosyloxybenzyl)-2-β-D-glucopyranosyl-2-isobutylmalate (dactylorhin A)  
 (W8);





and stereo-isomers and pharmaceutically acceptable salts thereof.

4. (Currently amended) The method according to claim 1, ~~characterized in that~~  
~~said compounds include stereo-isomers and pharmaceutical acceptable salts wherein the~~  
compound is a pharmaceutically acceptable salt.

5. (Currently amended) The method according to claim 1, ~~characterized in that~~  
~~said dementia includes wherein the animal has Alzheimer's disease, vascular dementia, and or a~~  
learning and or memory obstacle.

6. (Canceled).

7. (Canceled).

8. (Currently amended) A method for improving memory performance in an  
animal comprising:

providing administering a therapeutically effective dose of an extract of  
*Coeloglossum viride* (L.) Hartm. var. *bracteatum* (Willd.) Richter, said extract comprising  
ethanol soluble compounds. ~~and~~  
utilizing the extract in the manufacture of drugs for preventing or treating  
dementia.

9. (Currently amended) The method according to claim 8, ~~characterized in that~~  
~~said dementia includes wherein the animal has Alzheimer's disease, vascular dementia, or a and~~  
learning and or memory obstacle.

10. (Canceled).

11. (Canceled).

12. (Currently amended) The method according to claim 2, ~~characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts wherein the compound is a pharmaceutically acceptable salt.~~

13. (Currently amended) The method according to claim 3, ~~characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts wherein the compound is a pharmaceutically acceptable salt.~~

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (New) The method of claim 8, wherein the extract is prepared from rhizomes.

18. (New) The method of claim 8, wherein the animal is a human.

19. (New) The method of claim 18, wherein the human has Alzheimer's disease.

20. (New) The method of claim 8, further comprising administering at least one of: scopolamine, cycloheximide, and amyloid-beta peptides.